|
EU Semester Country Specific Recommendations: Improve patient access to medicine and ensure healthcare sustainability |
Medicines for Europe |
Thu, 05/24/2018 |
Health & Consumers |
|
EU Pharmaceutical Strategy Roadmap: high time to improve patient access to medicines and to apply the lessons from COVID-19 |
Medicines for Europe |
Thu, 06/04/2020 |
InfoSociety |
|
EU pharma strategy success depends on access to generic, biosimilar and value added medicines |
Medicines for Europe |
Wed, 11/25/2020 |
Health & Consumers |
|
EU must take the lead to ensure security of supply for medicines |
Medicines for Europe |
Wed, 06/16/2021 |
Health & Consumers |
|
EU must learn from Covid-19 to improve crisis preparedness and response for the future |
Medicines for Europe |
Tue, 11/09/2021 |
Health & Consumers |
|
EU must bolster biosimilar medicines policy to increase equity of access and bring much needed savings to healthcare budgets |
Medicines for Europe |
Thu, 05/25/2023 |
Health & Consumers |
|
EU must address barriers to continuous off-patent innovation and grasp opportunity for patients and healthcare |
Medicines for Europe |
Tue, 02/23/2021 |
Health & Consumers |
|
EU manufacturers call for urgent reforms to achieve reciprocity and a level-playing field in public procurement |
Medicines for Europe |
Mon, 09/30/2019 |
Health & Consumers |
|
EU Industrial strategy should be key to improving medicines supply chains |
Medicines for Europe |
Mon, 05/17/2021 |
Health & Consumers |
|
EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply |
Medicines for Europe |
Wed, 03/17/2021 |
Health & Consumers |
|
EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed |
Medicines for Europe |
Fri, 01/15/2021 |
Health & Consumers |
|
EU can do more for patients with smart use of biosimilar medicines |
Medicines for Europe |
Fri, 04/29/2022 |
Health & Consumers |
|
EU can do more for equitable access to medicines |
Medicines for Europe |
Fri, 01/13/2023 |
Health & Consumers |
|
Energy Council (TTE) – Medicines for Europe Open letter to European Energy Ministers and responsible European Commissioners on inflation and energy costs impacting the supply of essential generic medicines |
Medicines for Europe |
Wed, 09/28/2022 |
Health & Consumers |
|
EMA/HMA share definitive EU-wide position on biosimilar medicines interchangeability |
Medicines for Europe |
Tue, 09/20/2022 |
Health & Consumers |
|
EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms |
Medicines for Europe |
Wed, 03/18/2020 |
Health & Consumers |
|
Electronic product information: new report shows it is time to move from principles to action |
Medicines for Europe |
Fri, 02/25/2022 |
Health & Consumers |
|
Efficient use of pharmacovigilance data essential for patient safety |
Medicines for Europe |
Wed, 01/30/2019 |
Health & Consumers |
|
EBA and Medicines for Europe signed a memorandum of agreement to accelerate Ukraine's integration into the EU pharmaceutical market |
Medicines for Europe |
Thu, 06/22/2023 |
Health & Consumers |
|
Driving local excellence, delivering European results |
Medicines for Europe |
Tue, 11/06/2018 |
Health & Consumers |
|
Decisive action on medicines shortages should be included in pharmaceutical and industrial strategies |
Medicines for Europe |
Fri, 09/18/2020 |
Health & Consumers |
|
Crucial European Parliament vote vastly improves SPC manufacturing waiver |
Medicines for Europe |
Thu, 01/24/2019 |
Health & Consumers |
|
COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy |
Medicines for Europe |
Thu, 07/09/2020 |
Health & Consumers |
|
Court decision on Supplementary Protection Certificate (SPC) manufacturing waiver risks undermining its use |
Medicines for Europe |
Thu, 01/18/2024 |
InfoSociety |
|
Comprehensive SPC manufacturing waiver key for patient access to medicines, jobs and growth in Europe |
Medicines for Europe |
Mon, 05/28/2018 |
Health & Consumers, Social Europe & Jobs |
|
Competition policy essential for access to medicines |
Medicines for Europe |
Tue, 01/29/2019 |
Health & Consumers |
|
Commission study highlights market framework conditions are main driver for medicines shortages |
Medicines for Europe |
Fri, 12/10/2021 |
Health & Consumers |
|
Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs |
Medicines for Europe |
Wed, 10/18/2017 |
Health & Consumers |
|
CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court |
Medicines for Europe |
Thu, 09/20/2018 |
Health & Consumers |
|
Central & Eastern European patients have inequitable access to medicines for life-threatening conditions |
Medicines for Europe |
Mon, 04/25/2022 |
Health & Consumers |
